Skip to content

Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis

A Randomized Controlled Trial of Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02834819
Enrollment
18
Registered
2016-07-15
Start date
2013-09-30
Completion date
2015-09-30
Last updated
2020-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis

Keywords

bronchiolitis, hypoxia, hypertonic saline

Brief summary

The purpose of this study is to determine whether nebulized 3% hypertonic saline is more effective than the current standard of care in the treatment of viral bronchiolitis in children.

Detailed description

This will be a prospective, randomized controlled single-blinded study of patients 3-18 months of age presenting to the Children's Hospital Colorado ED during bronchiolitis season, diagnosed with mild to moderate bronchiolitis and persistent hypoxia and started on the Children's Hospital Colorado Home Oxygen pathway (see attached clinical care guideline). Investigators aim to enroll 220 patients. Patients will be identified by research assistants in the ED, based on physician diagnosis of bronchiolitis, with hypoxia requiring \< 0.5L oxygen by NC. A research assistant will approach the family and go through the informed consent process. If consent is obtained, the patient will then be randomized to one of the two study arms via a computer generated randomization table. In order to arrange for respiratory therapy, the research assistants will not be blinded. There will be an age block randomization scheme, and therefore patients aged 3-12 months will be randomized separately from patients 12.1-18 months to ensure equal distribution of age ranges in each arm. The experimental arm will consist of patients who receive a nebulized treatment of 4ml of 3% hypertonic saline, administered by a respiratory therapist, as well as supportive care as needed. Patients in the control arm will receive supportive care only, the current standard of care at Children's Hospital Colorado. The pharmacist will randomize patients as noted above. After consent is obtained the provider will perform a pre-intervention clinical severity score evaluation to patients in both study arms utilizing the clinical severity score tool described by Wang et al.19 Respiratory therapy will then provide the nebulized treatment for those patients randomized to receive hypertonic saline. Removal of equipment following treatment will aid in ensuring blinding of physicians to treatment arm. At 90 minutes after treatment with hypertonic saline or after the order is placed for patients in the control arm, patients in both arms will undergo a second clinical severity score by the provider. At that time the provider will turn off the oxygen administered to both treatment arms for a room air challenge. The RN will be notified that the patients are off oxygen therapy and will restart oxygen if patient has saturations \< 87% (as indicated by continuous pulse oximetry) and oxygen will be restarted at 0.5L by NC. Patients in both arms who are no longer requiring oxygen will be observed for a minimum of 4 hours to ensure they remain stable on room air, have appropriate oral intake, and sleep without de-saturation. At any point if a patient who was weaned off oxygen becomes hypoxic (saturations \< 87%), requiring \< 0.5L oxygen NC they will return to the home oxygen observation protocol. If during this period of observation any patient requires \> 0.5L oxygen during wake or sleep periods, is not taking adequate oral intake, demonstrates respiratory distress, or at physician discretion, patient may be admitted to the inpatient service for further management. Patients in both arms will receive follow-up phone calls to assess duration and amount of oxygen, as well as adverse outcomes. Patients discharged home on room air will receive 1 phone call on post-discharge day #7 (range 6-8). Patients discharged home on oxygen will receive a phone call on day #7 (range 6-8). Calls will be made for the study by the study investigators or by the Emergency Department (ED) research assistants. During the follow-up phone call, caregivers will be asked about Primary Care Physician (PCP) follow-up visits, any future scheduled PCP visits, any adverse events including increased work of breathing, increased oxygen requirement, repeat ED visits to researchers or other institutions, outside hospital admissions, intensive care unit admission or intubations, and any instructions for weaning oxygen given by PCP. If parents have questions or concerns, these questions will be directed to a nurse, fellow, or attending provider. Data from each subject will be collected on a data collection sheet for the follow-up phone call and PCP call. Data will then be entered into a database on a secure server and de-identified. All identifiers will be removed from the data set. The Electronic Health Record will be reviewed to verify return visits. If return visits are documented in EPIC (electronic health records software), data on type of admission (general pediatrics or intensive care unit) and any advanced airway intervention such as intubation, continuous positive airway pressure (CPAP).

Interventions

DRUG3% Nebulized Hypertonic Saline

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
3 Months to 18 Months
Healthy volunteers
No

Inclusion criteria

* Patients presenting to Children's Hospital Colorado ED * ≥3 to ≤18 months of age * Diagnosed with bronchiolitis * Have persistent hypoxia following initial supportive care measures as outlined by Children's Hospital Colorado Bronchiolitis Clinical Care Guideline * Started on Children's Hospital Colorado Home Oxygen Pathway

Exclusion criteria

* Patients who do not qualify for the Clinical Care Guideline for Home oxygen for Bronchiolitis * Previous history of wheezing * History of reactive airway disease * History of underlying heart disease * Require \>0.5L oxygen

Design outcomes

Primary

MeasureTime frameDescription
Hospitalization RateAt any point during enrollment visit or up to 7 days after enrollment visit.Effect of nebulized 3% hypertonic saline on hospitalization rate in children with bronchiolitis compared to those who receive the current standard of care
Number of Patients With Persistent HypoxiaAt baseline and 90 minutes post-interventionTo assess the effect of nebulized hypertonic saline on hypoxia in children with bronchiolitis compared to those who receive current standard of care.
Need for Supplemental Oxygen After DischargeAt time of discharge from the hospital through 7 days.To assess the effect of nebulized hypertonic saline on supplemental home oxygen requirement in children with bronchiolitis compared to those who receive the current standard of care.

Secondary

MeasureTime frameDescription
Adverse OutcomesDuring enrollment visit or within 7 days following enrollment visitRespiratory distress, increased oxygen requirement, advanced airway interventions (NIPPV or intubation).
Pre- Intervention Clinical Severity ScoreDuring Enrollment visit following randomization.Clinical severity score taken immediately following randomization, and prior to any intervention to assess change in baseline after intervention and compare change in scores, if any, between the two groups. The Scale utilized was the Clinical Severity Score from Wang et al, which measures respiratory distress in young children. The system assigns scores ranging from 0 to 3 for the following categories: respiratory rate, wheezing, retraction, and general condition. These category scores are then summed to come up with the final Clinical Severity Score. Total scores range from 0 to 12, with higher scores indicating greater severity/worse outcomes.
Hospital Admission After DischargeWithin 7 days following discharge from enrollment visitAdmission to any hospital institution within 7 days following enrollment visit
Post-intervention Clinical Severity ScoreDuring enrollment visit - 90 minutes after randomizationClinical severity score taken at time 90 minutes in both arms to assess any change in clinical severity score from baseline. The Scale utilized was the Clinical Severity Score from Wang et al, which measures respiratory distress in young children. The system assigns scores ranging from 0 to3 for the following categories: respiratory rate, wheezing, retraction, and general condition. These category scores are then summed to come up with the final Clinical Severity Score. Total scores range from 0 to 12, with higher scores indicating greater severity/worse outcomes.
Unscheduled Return ED VisitsCalled at 7 days post enrollment visit to assess any visit within 3 days of enrollment visitUnscheduled visit to ED within 3 days of enrollment visit. Patients in each group will be contacted 7 days after the enrollment visit to see if they had any unscheduled return ED visit within 3 days of the enrollment visit.

Participant flow

Participants by arm

ArmCount
Hypertonic Saline
Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed. 3% Nebulized Hypertonic Saline
9
No Treatment
Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed.
9
Total18

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDid not complete 7 day follow up call.50

Baseline characteristics

CharacteristicNo TreatmentHypertonic SalineTotal
Age, Categorical
<=18 years
9 Participants9 Participants18 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous255.33 days
STANDARD_DEVIATION 122.43
202.22 days
STANDARD_DEVIATION 109.37
228.77 days
STANDARD_DEVIATION 115.88
Region of Enrollment
United States
9 Participants9 Participants18 Participants
Sex: Female, Male
Female
6 Participants5 Participants11 Participants
Sex: Female, Male
Male
3 Participants4 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 9
other
Total, other adverse events
0 / 90 / 9
serious
Total, serious adverse events
0 / 90 / 9

Outcome results

Primary

Hospitalization Rate

Effect of nebulized 3% hypertonic saline on hospitalization rate in children with bronchiolitis compared to those who receive the current standard of care

Time frame: At any point during enrollment visit or up to 7 days after enrollment visit.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineHospitalization Rate2 Participants
No TreatmentHospitalization Rate1 Participants
Primary

Need for Supplemental Oxygen After Discharge

To assess the effect of nebulized hypertonic saline on supplemental home oxygen requirement in children with bronchiolitis compared to those who receive the current standard of care.

Time frame: At time of discharge from the hospital through 7 days.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineNeed for Supplemental Oxygen After Discharge9 Participants
No TreatmentNeed for Supplemental Oxygen After Discharge9 Participants
Primary

Number of Patients With Persistent Hypoxia

To assess the effect of nebulized hypertonic saline on hypoxia in children with bronchiolitis compared to those who receive current standard of care.

Time frame: At baseline and 90 minutes post-intervention

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineNumber of Patients With Persistent Hypoxia9 Participants
No TreatmentNumber of Patients With Persistent Hypoxia9 Participants
Secondary

Adverse Outcomes

Respiratory distress, increased oxygen requirement, advanced airway interventions (NIPPV or intubation).

Time frame: During enrollment visit or within 7 days following enrollment visit

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineAdverse Outcomes0 Participants
No TreatmentAdverse Outcomes0 Participants
Secondary

Hospital Admission After Discharge

Admission to any hospital institution within 7 days following enrollment visit

Time frame: Within 7 days following discharge from enrollment visit

Population: 5 patients did not complete the 7 day phone call and were not able to be analyzed for this outcome measure.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineHospital Admission After Discharge0 Participants
No TreatmentHospital Admission After Discharge0 Participants
Secondary

Post-intervention Clinical Severity Score

Clinical severity score taken at time 90 minutes in both arms to assess any change in clinical severity score from baseline. The Scale utilized was the Clinical Severity Score from Wang et al, which measures respiratory distress in young children. The system assigns scores ranging from 0 to3 for the following categories: respiratory rate, wheezing, retraction, and general condition. These category scores are then summed to come up with the final Clinical Severity Score. Total scores range from 0 to 12, with higher scores indicating greater severity/worse outcomes.

Time frame: During enrollment visit - 90 minutes after randomization

ArmMeasureValue (MEAN)Dispersion
Hypertonic SalinePost-intervention Clinical Severity Score2.22 score on a scaleStandard Deviation 1.48
No TreatmentPost-intervention Clinical Severity Score2.22 score on a scaleStandard Deviation 2.22
Secondary

Pre- Intervention Clinical Severity Score

Clinical severity score taken immediately following randomization, and prior to any intervention to assess change in baseline after intervention and compare change in scores, if any, between the two groups. The Scale utilized was the Clinical Severity Score from Wang et al, which measures respiratory distress in young children. The system assigns scores ranging from 0 to 3 for the following categories: respiratory rate, wheezing, retraction, and general condition. These category scores are then summed to come up with the final Clinical Severity Score. Total scores range from 0 to 12, with higher scores indicating greater severity/worse outcomes.

Time frame: During Enrollment visit following randomization.

ArmMeasureValue (MEAN)Dispersion
Hypertonic SalinePre- Intervention Clinical Severity Score3.8 score on a scaleStandard Deviation 1.8
No TreatmentPre- Intervention Clinical Severity Score2.7 score on a scaleStandard Deviation 2.04
Secondary

Unscheduled Return ED Visits

Unscheduled visit to ED within 3 days of enrollment visit. Patients in each group will be contacted 7 days after the enrollment visit to see if they had any unscheduled return ED visit within 3 days of the enrollment visit.

Time frame: Called at 7 days post enrollment visit to assess any visit within 3 days of enrollment visit

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Hypertonic SalineUnscheduled Return ED Visits0 Participants
No TreatmentUnscheduled Return ED Visits0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026